Atrial fibrillation patients with mental health conditions are less likely to be eligible for warfarin receipt, and those who are eligible receive warfarin at lower rates. Objectives: To characterize ...

A combined subgroup analysis of the similar trials NOAH—AFNET 6 and ARTESiA has revealed that patients with device-detected atrial fibrillation and concomitant vascular disease are at higher risk of ...

In patients with device-detected atrial fibrillation the risk of stroke appears low (1% per year) compared to patients with ECG-detected atrial fibrillation, even in patients with long episodes.

Objective: To evaluate data addressing use of anticoagulation in elderly patients with atrial fibrillation (AF), in particular those at risk of falls. Data Sources: Primary literature was identified ...

Blood thinners (anticoagulants) cause bleeding without preventing stroke in patients with atrial high rate episodes (AHRE), but without electrocardiogram (ECG)-diagnosed atrial fibrillation, according ...

Using a disease model, the current economic burden of stroke in the 2.3 million US patients with atrial fibrillation was estimated, and potential savings in direct costs obtainable by optimization of ...

Please provide your email address to receive an email when new articles are posted on . Data show early anticoagulation after acute stroke in people with atrial fibrillation is safe when indicated.

Background: There are a variety of periprocedural anticoagulation strategies for atrial fibrillation (AF) ablation, including the use of dabigatran. It is unclear which strategy is superior. Objective ...

Bottom Line: Mount Sinai researchers developed an AI model to make individualized treatment recommendations for atrial fibrillation (AF) patients-helping clinicians accurately decide whether or not to ...

Point-of-care coagulometers (the CoaguChek XS system and the INRatio2 PT/INR monitor) for self-monitoring coagulation status in people on long-term vitamin K antagonist therapy who have atrial ...

The efficacy of oral anticoagulation therapy for atrial fibrillation depends on preservation of the international normalized ratio within the established therapeutic range (2.0–3.0). Wide variation in ...